Recombinant human erythropoietin in anemia of prematurity.
Indian Pediatr
;
1999 Jan; 36(1): 17-27
Article
in English
| IMSEAR
| ID: sea-10758
ABSTRACT
OBJECTIVE:
To evaluate safety and efficacy of recombinant human erythropoietin (r-HuEPO)in reducing the need for red cell transfusions in anemia of prematurity.METHODS:
forty -two preterm infants (gestational age <32 weeks) were randomly assigned to a "treatment" group (r-HuEPO 400 units/kg every alternate day * 10 doses) or "no treatment" (control) group. All infants on enteral feeds received oral iron 3 mg/kg/day, graded up to 6 mg/kg/day.RESULTS:
Higher reticulocyte counts in week 2 and 3 and higher hemoglobin levels in week 4 were noted after treatment with r-HuEPO. Despite stumulated erythropoiesis, the frequency of transfusions could not be reduced with r-HuEPO therapy.Overall, Phlebotomy losses, frequency and volume of redcell transfusions were significantly more in neonates with birthweight <1000 grams compared with those with birthweight >1000 grams (p<0.05). Associated side effects of r-HuEPO such as neutropenia,sepsis, hypertension or increased risk of late death did not occur.CONCLUSION:
r-HuEPO therapy was safe without any side effects.Inability of r-HuEPO therapy to minimize red cell transfusions for anemia of prematurity may be explained by a relatively strict red-cell transfusion policy and the desired degree of treatment effect.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Reticulocytes
/
Safety
/
Birth Weight
/
Female
/
Humans
/
Male
/
Hemoglobins
/
Infant, Newborn
/
Infant, Premature
/
Administration, Oral
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Language:
English
Journal:
Indian Pediatr
Year:
1999
Type:
Article
Similar
MEDLINE
...
LILACS
LIS